Suchergebnisse - "Pernot, Simon"

PubPharm (8)

1

FFCD 1709-SIRTCI phase II trial : Selective internal radiation therapy plus Xelox, Bevacizumab and Atezolizumab in liver-dominant metastatic colorectal cancer

enthalten in: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2022

von Randrian, V. | Pernot, S. | Le Malicot, K. | +24

2

Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE) : A Single-arm, Open-label, Phase II Trial

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2021

von Cousin, S. | Cantarel, C. | Guegan, J. | +11

3

Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC) : A Phase II Study (FFCD 1302)

enthalten in: Clinical colorectal cancer | 2020

von Lapeyre-Prost, A. | Pernot, S. | Sigrand, J. | +11

4

Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma : The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)

enthalten in: European journal of cancer (Oxford, England : 1990) | 2020

von Rinaldi, Y. | Pointet, A. | Khemissa Akouz, F. | +71

5

Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer : a Phase 2 study

enthalten in: British journal of cancer | 2020

von Pernot, S. | Pellerin, O. | Artru, P. | +12

6

Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance

enthalten in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association | 2020

von Pernot, S. | Terme, M. | Radosevic-Robin, N. | +19

7

Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02) : a multicentre, single-arm, phase 2 study

enthalten in: The Lancet. Oncology | 2018

von Kim, S. | François, E. | André, T. | +24

CommentIn: Lancet Oncol. 2018 Aug;19(8):1009-1011. - PMID 30042062

8

Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma : a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)

enthalten in: BMC cancer | 2017

von Kim, S. | Jary, M. | André, T. | +26

1
[1]